Study suggests that autophagy inhibitors could improve efficacy of chemotherapies

October 24, 2016

Chemotherapies treat cancer by killing tumor cells, but certain types of chemotherapy can also drive an immune system response to target and destroy the remaining tumor cells.

This immune targeting is elicited by molecules called damage-associated molecular patterns (DAMPS) that are released when a cell is killed. DAMPs are normally degraded in a process called autophagy, and it has been suggested that limiting the efficiency of autophagy could improve the efficacy of some chemotherapies. However, because autophagy is also critical to other aspects of immune system function, it is possible that inhibiting autophagy could backfire and compromise chemotherapy-driven immune targeting instead.

This week in the JCI, research led by Jayanta Debnath at UCSF has shown that inhibiting autophagy does not impair the immune response to tumors during chemotherapy, providing support for the idea that combining autophagy inhibitors with certain chemotherapies may aid cancer treatment.

In mouse models of cancer, treatment with autophagy inhibitors did not affect how immune cells targeted tumors during chemotherapy, in spite of other changes in general . These results suggest that inhibiting may be a safe combinatorial treatment to enhance the cancer-killing effects of certain chemotherapies.

Explore further: Discovery reveals how protective immune cells protect themselves

More information: Hanna Starobinets et al, Antitumor adaptive immunity remains intact following inhibition of autophagy and antimalarial treatment, Journal of Clinical Investigation (2016). DOI: 10.1172/JCI85705

Related Stories

Zombie cancer cells eat themselves to live

April 5, 2014

A University of Colorado Cancer Center study recently published in the journal Cell Reports and presented today at the American Association for Cancer Research (AACR) Annual Conference 2014 shows that the cellular process ...

Researchers find new target for kidney cancer therapy

November 10, 2014

Cincinnati Cancer Center (CCC) researchers have discovered that a membrane channel, Transient Receptor Potential Melastatin 3, or TRPM3, promotes growth of kidney cancer tumors, and targeting this channel therapeutically ...

Research reveals mechanism behind cell protein remodeling

September 3, 2014

The remodeling of a kitchen or bathroom changes the appearance of the room and improves its functionality. As investigators at Rutgers Cancer Institute of New Jersey and Rutgers and Princeton Universities have demonstrated, ...

Recommended for you

Cancer hijacks natural cell process to survive

June 26, 2017

Cancer tumours manipulate a natural cell process to promote their survival suggesting that controlling this mechanism could stop progress of the disease, according to new research led by the University of Oxford.

Targeted drug shows promise in rare advanced kidney cancer

June 23, 2017

Some patients with a form of advanced kidney cancer that carries a poor prognosis benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by a Dana-Farber ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.